Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens

Leuk Lymphoma. 2004 Jul;45(7):1407-11. doi: 10.1080/10428190410001663671.

Abstract

Treatment with intensive chemotherapy regimens is frequently complicated by severe thrombocytopenia. During the period of severe thrombocytopenia, anticoagulant treatment is not uncommonly indicated for thromboembolic events or thromboprophylaxis in these patients. We report 10 hematological patients treated with intensive chemotherapy protocols that were anticoagulated with enoxaparin for catheter related central venous thrombosis and thromboprophylaxis. During the period of severe thrombocytopenia the dosages of enoxaparin were reduced and no major bleeding occurred. Based on our experience we suggest that reduced dosages of low molecular weight heparins may be used relatively safely during transient severe thrombocytopenia.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Catheterization, Central Venous / adverse effects
  • Combined Modality Therapy
  • Enoxaparin / adverse effects
  • Enoxaparin / therapeutic use*
  • Female
  • Hematologic Neoplasms / blood
  • Hematologic Neoplasms / drug therapy
  • Hematologic Neoplasms / therapy
  • Hemorrhage / chemically induced
  • Humans
  • Male
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation
  • Thrombocytopenia / chemically induced*
  • Thrombosis / blood
  • Thrombosis / etiology
  • Thrombosis / prevention & control*

Substances

  • Anticoagulants
  • Enoxaparin